Historical wat News Stories
Waters Stock Slips After BD Integration and Q4 Beat
Waters Corp. reported solid Q4 results and closed its acquisition of BD’s biosciences/diagnostics unit, but integration uncertainty and near-term execution risks weighed on WAT shares. Analysts remain mixed-to-positive as investors watch synergy progress, guidance cadence, and diagnostics revenue ramp.
Waters (WAT) Slumps After BD Spin-Off Integration.
Waters Corp reported a solid Q4 beat but issued conservative 2026 guidance after completing the BD Biosciences & Diagnostics spin-off merger. The deal adds roughly $3B in revenue but pressures margins and raised investor concerns about near-term integration risk, driving recent WAT underperformance.
Waters (WAT) Q4 Beat, BD Deal Sparks Guidance Dip.
Waters reported a Q4 earnings beat driven by recurring revenue, but its 2026 guidance—reflecting the addition of BD’s Biosciences & Diagnostic unit—triggered a sharp stock decline as integration costs and a near-term margin reset weighed on sentiment.
WAT Drops After Guidance; BD Merger Nears Close
Waters Corporation (WAT) cleared shareholder approval for a major BD biosciences acquisition and is set to close the deal imminently. Strong Q4 results were offset by guidance that signaled near-term margin pressure and integration complexity, prompting heightened volatility and a meaningful share-price decline. This article synthesizes the concrete events shaping WAT this week and what investors should watch next.